Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04202926
Other study ID # TFYuan
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 30, 2019
Est. completion date October 30, 2023

Study information

Verified date November 2023
Source Shanghai Mental Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A growing body of evidence suggests a wide range of brain areas including medial prefrontal cortex (mPFC), dorsolateral prefrontal cortex (DLPFC) and other subcortical regions, such as anterior cingulate cortex (ACC) are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial magnetic stimulation (rTMS) over dorsolateral prefrontal cortex reduces craving for meth dependences. Specifically, the H7 coil induces a magnetic field can target mPFC and ACC. In this study, the investigators investigated whether repeated dTMS intervention of medial prefrontal and cingulate cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.


Description:

The study will be conducted at the drug rehabilitation center in China. The whole procedure includes enrollment, pre-intervention evaluation, intervention (for 3 weeks, 5 times a week, 15 times in total), post-intervention evaluation and one month follow up evaluation. In enrollment session, participants are recruited according to inclusion criteria. In the pre-intervention evaluation, firstly, participants need complete a questionnaire to assess their demographic information, drug addiction history and drug abstinence. And then are assigned to either 10Hz group or sham group according to the counterbalance of their basic demographic and drug use information. Then, participants need complete craving, cognitive ability and electroencephalogram (EEG) assessment. For craving assessing, participants are shown a video of methamphetamine usage for 5 minutes, and then rated on the visual analogue scale (0 means completely undesired and 100 means extremely wanting) to report their craving for methamphetamine. For cognitive ability and EEG signal assessing, the whole process is conducted on the computer according to instructions. In the intervention session, dTMS was administered using a TMS stimulator (Magstim, U.K.) equipped with a unique H-shaped coil design. The H-coil version used in this study was the H7 (Brainsway, Jerusalem, Israel). When placed 4-5 cm anterior to the foot motor cortex and used at 100% of the leg resting motor threshold (RMT), the H7 coil stimulates the dorsal mPFC and ACC bilaterally. A participant's RMT was determined before the first treatment and at the beginning of each week by ascertaining the coil position that elicited the minimal involuntary contractions of the feet (three of six attempts). The 10Hz group received 10 Hz dTMS at 100% of RMT, with 3-second pulse and 17-second intervals, for a total of 50 trains and 1500 pulses per session. The sham group received treatment with identical technical parameters, which induced scalp sensations but without penetration of the electric field into the brain. Post-intervention evaluation and one month follow up evaluation are the same as in pre-intervention evaluation. To ensure study quality, some measures are taken as bellow: Researchers and drug rehabilitation staff will work together in whole process and the data will be converted into electronic versions once finishing each evaluation. In the intervention, patients, operators, and raters were blind to treatment condition. Each patient is assigned a magnetic card that determined the coil (real or sham) in the helmet and raters are not present while treatments are administered. After each treatment times, any side effect from participant's report are recorded to assure the safety and feasibility. Statistical analyses are performed using SPSS 21.0. The principal statistical analysis is performed using repeated-measures analysis of variance and regression analysis. All missing data will be recorded and marked.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date October 30, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Methamphetamine dependents - middle school degree or above Exclusion Criteria: - Have contraindications to rTMS (head trauma, epilepsy or history of epilepsy, metal implant etc.) - psychiatric illnesses - intellectual impairment (IQ<90)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
real coil
active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
sham coil
sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses

Locations

Country Name City State
China Nanjing Dalianshan Addiction Rehab Center Nanjing

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

References & Publications (6)

Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2019 Nov 1;176(11):931-938. doi: 10.1176/appi.ajp.2019.18101180. Epub 2019 May 21. — View Citation

Dunlop K, Hanlon CA, Downar J. Noninvasive brain stimulation treatments for addiction and major depression. Ann N Y Acad Sci. 2017 Apr;1394(1):31-54. doi: 10.1111/nyas.12985. Epub 2016 Feb 5. — View Citation

Liu Q, Shen Y, Cao X, Li Y, Chen Y, Yang W, Yuan TF. Either at left or right, both high and low frequency rTMS of dorsolateral prefrontal cortex decreases cue induced craving for methamphetamine. Am J Addict. 2017 Dec;26(8):776-779. doi: 10.1111/ajad.12638. Epub 2017 Nov 14. — View Citation

Liu T, Li Y, Shen Y, Liu X, Yuan TF. Gender does not matter: Add-on repetitive transcranial magnetic stimulation treatment for female methamphetamine dependents. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:70-75. doi: 10.1016/j.pnpbp.2018.12.018. Epub 2018 Dec 31. — View Citation

Shen Y, Cao X, Tan T, Shan C, Wang Y, Pan J, He H, Yuan TF. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. Biol Psychiatry. 2016 Aug 1;80(3):e13-4. doi: 10.1016/j.biopsych.2016.02.006. Epub 2016 Feb 12. No abstract available. — View Citation

Su H, Zhong N, Gan H, Wang J, Han H, Chen T, Li X, Ruan X, Zhu Y, Jiang H, Zhao M. High frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex for methamphetamine use disorders: A randomised clinical trial. Drug Alcohol Depend. 2017 Jun 1;175:84-91. doi: 10.1016/j.drugalcdep.2017.01.037. Epub 2017 Mar 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other side effect measurements Side effect scale, including headache, pricking, sleeplessness etc. every day after each intervention time for the 3 weeks intervention time period
Primary Changes of Cue-induced craving and ERP Subjective craving (cue induced, 0-100 based VAS, craving scale) and drug cue-ERP (P300 etc. measured) the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of cognition: behavioral inhibition using cognitive tasks: stop-signal task the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of cognition: working memory using cognitive tasks: n-back task the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of depression status depression (Beck Depression inventory scale), high score means worse depression the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of anxiety status Anxiety (Beck anxiety inventory scale), higher score means worse anxiety the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of sleep status sleep status measurements (Pittsburgh Sleep Quality Index scale), higher score means worse sleep the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of impulsivity Impulsivity scale (The Barratt Impulsiveness Scale), higher score means higher impulsivity the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
Secondary Changes of resting EEG network resting EEG signal (Alpha, Beta, Theta, etc) measurement with 128 Channel EGI system the day before intervention, 3 weeks after intervention, 1 month after intervention, up to 3 months after intervention
See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT04449055 - Pilot TMS for Methamphetamine Use Disorder N/A
Completed NCT06288997 - tACS Intervention for Methamphetamine Addiction N/A
Recruiting NCT05162391 - Inflammation in Methamphetamine and STIs (IMSTI) N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Not yet recruiting NCT03748875 - The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents N/A
Recruiting NCT03341078 - Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users Phase 2
Active, not recruiting NCT03910608 - Paired Associative Stimulation in Methamphetamine Addiction N/A
Terminated NCT05283304 - Monthly Injectable BUP for MA Use Disorder (MURB) Trial Phase 2
Completed NCT04563962 - Contingency Management for PrEP Adherence and/or Methamphetamine Use N/A
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A
Active, not recruiting NCT05034874 - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 Phase 2
Recruiting NCT06027814 - MHealth Incentivized Adherence Plus Patient Navigation N/A
Completed NCT04544124 - Delivering Contingency Management in Outpatient Addiction Treatment N/A
Completed NCT01217970 - Safety Interaction Trial Ibudilast and Methamphetamine Phase 1
Completed NCT03825536 - Effect of Methamphetamine on Residual Latent HIV Disease Study Phase 4
Recruiting NCT03470480 - rTMS for Craving in Methamphetamine Use Disorder N/A
Recruiting NCT05128071 - PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT) Early Phase 1